Your AI-Trained Oncology Knowledge Connection!
“The dMMR population, which are patients who have deficiency in their mismatch repair proteins, had the most pronounced impact in PFS, and we’re seeing that trend for prolonged periods of time; we may be curing many of these patients,” said Ritu Salani, MD.
Conditional marketing authorization for epcoritamab in the European Union is based on findings from the phase 1/2 EPCORE NHL-1 trial.
Findings from the MARIPOSA trial support the FDA approval of frontline amivantamab/lazertinib in advanced or metastatic EGFR-mutant NSCLC.
In Japan, liso-cel recently received approval for patients with previously treated relapsed/refractory follicular lymphoma.
The Melanoma Research Alliance mourns the passing of Jeffrey S. Weber, MD, PhD, a pioneer in developing immunotherapy for patients with melanoma.
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Data from the DESTINY-Breast06 trial support the FDA breakthrough therapy designation for T-DXd in HR–positive, HER2-low, or HER2-ultralow breast cancer.
Developers plan to submit a sBLA for tafasitamab in relapsed/refractory follicular lymphoma based on data from the inMIND trial.
Ritu Salani, MD, highlights data from the RUBY trial supporting the FDA approval of dostarlimab/chemotherapy for primary advanced endometrial cancer.
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
The phase 3 RUBY trial evaluated dostarlimab in combination with carboplatin/paclitaxel in patients with primary advanced or recurrent endometrial cancer.
The FDA has set a Prescription Drug User Fee Act date of February 17, 2025, to approve vimseltinib for patients with tenosynovial giant cell tumor.
Phase 1/2 AUGMENT-101 study results revealed quick and lasting responses for patients with relapsed/refractory KMT2Ar acute leukemia.
Phase 1 AC699-001 results evaluating the safety and efficacy of AC699 in patients with breast cancer subtypes support the Fast Track designation.
Results from the phase 3 AEGEAN trial led to the approval of neoadjuvant and adjuvant durvalumab for patients with resectable NSCLC.
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Data from the phase 3 ADRIATIC trial support the supplemental biologics license application for durvalumab in this limited-stage SCLC population.
Investigators developed a risk model to assess whether upfront surgery can improve prognoses in a subset of cN2 diseases such as single-station N2 NSCLC.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.
CytoDyn intends to submit its final study protocol to the FDA, engage a clinical research organization, and complete preparatory work to initiate the phase 2 trial.
Subgroup analysis data from DUO-E support the European approval of durvalumab-based treatment in primary or recurrent endometrial cancer.
Findings from a population-based study suggest patients with POI may need genetic counseling regarding future risk of reproductive cancers.
Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma.
